Literature DB >> 21283016

Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity.

Mohammad M Sajadi1, Yongjun Guan, Anthony L DeVico, Michael S Seaman, Mian Hossain, George K Lewis, Robert R Redfield.   

Abstract

OBJECTIVE: To examine the relationship between HIV-1 antigenic load (plasma RNA copies/mL) and broad HIV-1 neutralizing antibody activity.
METHODS: Plasma from 120 HIV-1-infected patients, including HIV-1 natural viral suppressors (similar to elite controllers), was tested for neutralization against 15 Tier 1/Tier 2 HIV-1 pseudoviruses. Broad HIV-1 neutralizing antibody activity was confirmed with immunoglobulin G and heterlogous clade testing (18 pseudoviruses from Clades A, C, and CRF02_AG). Statistical analysis was performed to determine factors associated with broad HIV-1 neutralizing antibody activity.
RESULTS: Ten individuals with broad HIV-1 neutralizing antibody activity were identified. These individuals had a median CD4 count of 589 cells per microliter (range 202-927), 1611 HIV-1 RNA copies per milliliter (range 110-8964), and 13 years since HIV diagnosis (range 1-22). There was a significant correlation between the presence of broadly neutralizing antibodies in those with HIV-1 RNA between 100 and 10,000 copies per milliliter compared with those <100 or >10,000 copies per milliliter (P = 0.0003 and 0.0245, respectively). Individuals with HIV-1 RNA 100-10,000 copies per milliliter had a higher number of Tier 2 viruses neutralized compared with the <100 or >10,000 copies per milliliter groups (P ≤ 0.0001 and P = 0.076, respectively). Male sex was associated with broad HIV-1 neutralizing antibody activity (P = 0.016).
CONCLUSIONS: These results indicate that low but persistent HIV antigen expression correlates with broad HIV-1 neutralizing antibody activity. At higher levels of plasma viremia, neutralization titers were diminished. Conversely, at lower levels, there seems to be insufficient antigen stimulation to maintain high neutralization titers. These findings may have important implications in furthering the understanding of the humoral response to HIV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21283016      PMCID: PMC3110998          DOI: 10.1097/QAI.0b013e3182100c1b

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  18 in total

1.  A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.

Authors:  D Cecilia; C Kleeberger; A Muñoz; J V Giorgi; S Zolla-Pazner
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.

Authors:  T Harrer; E Harrer; S A Kalams; T Elbeik; S I Staprans; M B Feinberg; Y Cao; D D Ho; T Yilma; A M Caliendo; R P Johnson; S P Buchbinder; B D Walker
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-01       Impact factor: 2.205

5.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.

Authors:  Y J Zhang; C Fracasso; J R Fiore; A Björndal; G Angarano; A Gringeri; E M Fenyö
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

7.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Authors:  A K Pilgrim; G Pantaleo; O J Cohen; L M Fink; J Y Zhou; J T Zhou; D P Bolognesi; A S Fauci; D C Montefiori
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

8.  Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1.

Authors:  Punnee Pitisuttithum; Phillip W Berman; Benjaluck Phonrat; Pravan Suntharasamai; Suwanee Raktham; La-Ong Srisuwanvilai; Krit Hirunras; Dwip Kitayaporn; Jaranit Kaewkangwal; Sricharoen Migasena; Haynes W Sheppard; Elizabeth Li; Marlene Chernow; Michael L Peterson; Riri Shibata; William L Heyward; Donald P Francis
Journal:  J Acquir Immune Defic Syndr       Date:  2004-09-01       Impact factor: 3.731

9.  Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome.

Authors:  E Barker; C E Mackewicz; G Reyes-Terán; A Sato; S A Stranford; S H Fujimura; C Christopherson; S Y Chang; J A Levy
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.

Authors:  Anne Piantadosi; Dana Panteleeff; Catherine A Blish; Jared M Baeten; Walter Jaoko; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

View more
  22 in total

1.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

2.  Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.

Authors:  Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico
Journal:  Cell       Date:  2018-05-03       Impact factor: 41.582

3.  Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Authors:  Carolina B Ferreira; Alberto Merino-Mansilla; Anuska Llano; Ignacio Pérez; Isabel Crespo; Laia Llinas; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

4.  Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Authors:  D Noah Sather; Sara Carbonetti; Jenny Kehayia; Zane Kraft; Iliyana Mikell; Johannes F Scheid; Florian Klein; Leonidas Stamatatos
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

5.  Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Authors:  Raiees Andrabi; M A Makhdoomi; Rajesh Kumar; Manju Bala; Hilal Parray; Arjun Gupta; Ankita Kotnala; Velpandian Thirumurthy; Kalpana Luthra
Journal:  J Clin Immunol       Date:  2014-03-29       Impact factor: 8.317

Review 6.  Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.

Authors:  Rowena E Johnston; Mary M Heitzeg
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

7.  The Brief Case: Confirmed Positive HIV-1 Serologic Screening but Undetectable RNA Virus Load in a Pregnant Woman.

Authors:  Rohan P Joshi; Carlos A Gomez; David Steiner; Natali Aziz; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2017-12       Impact factor: 5.948

Review 8.  HIV controllers: a multifactorial phenotype of spontaneous viral suppression.

Authors:  Jacques Thèze; Lisa A Chakrabarti; Benoît Vingert; Filippos Porichis; Daniel E Kaufmann
Journal:  Clin Immunol       Date:  2011-08-04       Impact factor: 3.969

9.  Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Authors:  Yongjun Guan; Marzena Pazgier; Mohammad M Sajadi; Roberta Kamin-Lewis; Salma Al-Darmarki; Robin Flinko; Elena Lovo; Xueji Wu; James E Robinson; Michael S Seaman; Timothy R Fouts; Robert C Gallo; Anthony L DeVico; George K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-13       Impact factor: 11.205

10.  Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens.

Authors:  Clarisa M Buckner; Lela Kardava; Xiaozhen Zhang; Kathleen Gittens; J Shawn Justement; Colin Kovacs; Adrian B McDermott; Yuxing Li; Mohammad M Sajadi; Tae-Wook Chun; Anthony S Fauci; Susan Moir
Journal:  J Infect Dis       Date:  2016-04-27       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.